TY  - JOUR
AU  - Petrillo, Angelica
AU  - Pappalardo, Annalisa
AU  - Calabrese, Filomena
AU  - Tirino, Giuseppe
AU  - Pompella, Luca
AU  - Ventriglia, Jole
AU  - Laterza, Maria Maddalena
AU  - Caterino, Marianna
AU  - Sforza, Vincenzo
AU  - Iranzo, Vega
AU  - Biglietto, Maria
AU  - Orditura, Michele
AU  - Ciardiello, Fortunato
AU  - Conzo, Giovanni
AU  - Molino, Carlo
AU  - De Vita, Ferdinando
PY  - 2019
TI  - First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
JF  - Journal of Gastrointestinal Oncology; Vol 10, No 5 (October 01, 2019): Journal of Gastrointestinal Oncology
Y2  - 2019
KW  - 
N2  - Background: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC.   Methods: We retrospectively analyzed the data of 64 mPC patients (≥65 years old) treated according to the MPACT schedule.   Results: Median age was 69.5 years (range, 65–80 years); after a median of 5 cycles administered (range, 1–12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI: 6.3–9.6) and median OS was 12.0 months (95% CI: 8.4–15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival.   Conclusions: Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the “daily clinical practice” geriatric population.
UR  - https://jgo.amegroups.org/article/view/29758